Pfizer (NYSE:PFE) refuses to take no for an answer in its pursuit of the next great pharma mega merger.
Its target, AstraZeneca (NYSE:AZN), recently rebuffed a higher bid, $106 billion in a more attractive cash/stock mix -- however the deal was still not attractive enough for the British pharma's management. Pfizer has also worked to hard to keep the U.K. government from standing in the way of the deal, agreeing to keep jobs on that side of the Atlantic.
In this episode of Market Check-Up, the Motley Fool's health-care focused investing show, analysts David Williamson and Michael Douglass discuss the details of the deal and why AstraZeneca turned it down, and why Pfizer isn't going silently into the night.
Investors should watch the video below and then stay tuned for The Fool's analysis of Pfizer's quarterly results on Monday.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.
3 Scorching-Hot Healthcare Stocks -- Are They Buys?
These three companies gained at least 400% in 2017. Can the good times continue?